Stockscreener 앱 받기
9.855
1.60%
-0.125
전일 마감가:
$9.98
열려 있는:
$9.74
하루 거래량:
311.05K
Relative Volume:
1.00
시가총액:
$619.37M
수익:
-
순이익/손실:
$-168.02M
주가수익비율:
-2.1844
EPS:
-4.5116
순현금흐름:
$-152.10M
1주 성능:
-16.50%
1개월 성능:
-27.10%
6개월 성능:
-51.98%
1년 성능:
-31.04%
1일 변동 폭
$9.64
$10.05
1주일 범위
$9.64
$11.58
52주 변동 폭
$9.64
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
명칭
Dbv Technologies Adr
전화
33(0)155427878
주소
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
9.855 | 726.53M | 0 | -168.02M | -152.10M | -4.5116 |
VRTX
Vertex Pharmaceuticals Inc
|
507.36 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
746.76 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
191.20 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
931.55 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.61 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 개시 | Guggenheim | Buy |
| 2025-05-29 | 재개 | Goldman | Sell |
| 2023-01-04 | 업그레이드 | Societe Generale | Hold → Buy |
| 2022-12-16 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-05-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-09-14 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-01-22 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2020-11-02 | 업그레이드 | Societe Generale | Sell → Hold |
| 2020-08-06 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2020-08-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-01-09 | 업그레이드 | Stifel | Hold → Buy |
| 2019-12-16 | 개시 | Citigroup | Buy |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-06-17 | 개시 | Goldman | Buy |
| 2018-12-20 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-12-20 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-10-31 | 업그레이드 | Societe Generale | Sell → Hold |
| 2017-10-24 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2017-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | 개시 | Deutsche Bank | Buy |
| 2017-03-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2016-09-26 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-03 | 개시 | Barclays | Overweight |
| 2015-10-23 | 개시 | BofA/Merrill | Buy |
모두보기
Dbv Technologies Adr 주식(DBVT)의 최신 뉴스
DBV Technologies Submits FDA Biologics License Application for VIASKIN Peanut Patch in Children Ages 4-7 - Kalkine Media
Citizens reiterates DBV Technologies stock rating on BLA milestone - Investing.com
DBV Technologies Announces Submission of Biologics License - GlobeNewswire
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years - GlobeNewswire Inc.
DBV Technologies S.A. (DBVT) Stock Price, News, Quote & History - Yahoo! Finance Canada
DBV technologies S.A. (ADR) (DBV1.SG) Q2 FY2026 earnings call transcript - Yahoo Finance
European ADRs Rose Late Thursday Morning, Led By Biotech - Finimize
DBVT Slides As DBV Technologies Leads Biotech ADR Losers - StocksToTrade
DBVT Slides As DBV Technologies Leads European Biotech Declines - timothysykes.com
DBV Technologies at Cantor conference: peanut allergy push advances By Investing.com - Investing.com UK
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Eastern Progress
Azitra Inc (AZTR) Peer Comparison – Compare with Others - Value Research
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
DBV Technologies S.A.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
DBV Technologies to Participate in Upcoming September Investor Conferences - GlobeNewswire
A food-allergy treatment company will join three New York events in September - Stock Titan
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
European ADRs Edged Higher As Biotech Led The Pack - Finimize
DBV Technologies (NASDAQ:DBVT) Shares Up 6.2%Here's Why - MarketBeat
European ADRs Started The Week Slightly Higher In US Trading - Finimize
MPM BioImpact LLC discloses 6.2% stake in DBV Technologies (DBVT) - Stock Titan
DBV technologies S.A. (ADR) (DBV1.SG) balance sheet - Yahoo Finance UK
DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4%Time to Buy? - MarketBeat
RA Capital discloses DBV Technologies (DBVT) 5.8% ownership via ADS holding - Stock Titan
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq - manilatimes.net
DBV Technologies Announces Sale of Approximately $50 - GlobeNewswire
Form S-3ASR DBV TECHNOLOGIES S.A. For: 27 July By Investing.com - Investing.com Canada
Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim - The Globe and Mail
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside (NASDAQ:DBVT) - Seeking Alpha
DBV Technologies on Track for Lowest Close Since December 2025 -- Data Talk - Moomoo
We Think DBV Technologies (EPA:DBV) Needs To Drive Business Growth Carefully - Simply Wall Street
DBV Technologies stock falls on $150M share offering plan - Investing.com
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
Citizens reiterates Market Outperform on DBV Technologies stock, $55 target - Investing.com
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies narrows Q2 loss, funds operations into Q3 2027 - scanx.trade
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report - markets.businessinsider.com
DBV Technologies (NASDAQ: DBVT) sees $174.9M cash and Q3 2027 runway - Stock Titan
DBV Technologies Announces the Filing of its 2026 Half-Year - GlobeNewswire
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 - markets.businessinsider.com
DBV Technologies' July 16 webcast will cover Q2 results - Stock Titan
ETFs Investing in DBV Technologies SA Sponsored ADR Stocks - TradingView
Europe’s US-Listed ADRs Slipped Late Tuesday Morning - Finimize
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - markets.businessinsider.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing - Stock Titan
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing - The Manila Times
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A40WEX Forecast — Price Target — Prediction for 2027 - TradingView
Dbv Technologies Adr (DBVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Dbv Technologies Adr 주식 (DBVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Jan 29 '26 |
Sale |
4.86 |
534 |
2,595 |
144,995 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 17 '25 |
Sale |
4.85 |
2,076,990 |
10,070,232 |
8,595,472 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
0.77%
1.15%
자본화:
|
볼륨(24시간):